Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain
Unknown statusNCT04763252
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
Chronic pain affects at least 10% of the global population but is often poorly managed, given the variable efficacy of available pharmacological treatments and the limited accessibility of multidisciplinary interventions. The legalization of cannabis in at least 14 countries and the increasing regulatory approval of cannabis preparations and synthetic cannabinoids and analogues have led to a growing interest in the use of medical cannabis products to manage chronic pain. This use is supported by research demonstrating important interactions between cannabinoids and the human endocannabinoid system and pain modulation pathways. While medical cannabis products are increasingly available to practitioners who treat pain, there is little evidence-based guidance for prescribing or titrating these treatments to manage chronic non-cancer pain. This prospective registry aims to assemble real-world data regarding the use of Spectrum Therapeutics (ST) medical cannabis products in subjects with chronic non-cancer pain in Canada. The registry will also assess treatment outcomes, including pain and related symptoms, global impressions of improvement, and change in concomitant pain medications (opioid use in particular), to better inform the utility of ST products for chronic non-cancer pain management. Primary Objective: • To describe patterns of physician selection of Spectrum Therapeutics (ST) medical cannabis treatment regimen, expressed as average daily dose of THC and CBD (in mg), and mode of administration (ingested or inhaled), in the management of chronic non-cancer pain in countries where these products are commercially available. Secondary Objectives: * To describe subject product and dose adjustment (under medical follow-up) over time. * To assess outcomes of treatment, including pain relief and effects on sleep, daily functioning, and quality of life. * To assess global impressions of treatment effectiveness as reported by subjects and physicians. * To assess changes …
Study details
- Official title
- Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain
- Conditions
- Interventions
- Other: Spectrum Therapeutics cannabis products
- Sponsor
- Canopy Growth Corporation
- Start date
- 2021-01-25
- Primary completion
- 2023-07-30
- Sex
- All
- Age range
- from 25 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Subject ≥ 25 years of age with a diagnosis of chronic non-cancer pain defined as pain lasting or recurring over a period \> 3 months (IASP-ICD-11 classification, refer to Appendix 6). 2. Subject is, in the physician's opinion, a candidate for medical cannabis treatment. Candidate status will be determined based on local regulations, common clinical practice, available guidelines and scientific literature, and the physician's expertise or experience with medical cannabis products. 3. Subject received a prescription/authorization for a product in the medical channel of Spectrum Therapeutics. 4. Subject is able to read and understand the informed consent form and complete the study questionnaires. Exclusion Criteria: 1. Subject refuses to provide informed consent or participate in any aspect of the study. 2. Subject is pregnant or lactating. 3. Subject has a history of psychosis or schizophrenia (or other significant psychiatric disorder), including among first-degree relatives. 4. Subject has a suspected or confirmed cardiovascular disease. 5. Subject is a liver transplant recipient or has severely compromised liver function.
Canadian sites (1)
| Facility | City | Province |
|---|---|---|
| Burrard Pain Doctors | Vancouver | British Columbia |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04763252